If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine…
Month: November 2020
ObsEva SA to present at Jefferies Virtual London Healthcare Conference, November 17 – 19, 2020
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancy Maternal, fetal and neonatal safety comparable to…
ObsEva SA to present at Jefferies Virtual London Healthcare Conference, November 17 – 19, 2020
Geneva, Switzerland and Boston, MA – November 13, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
Geneva, Switzerland and Boston, MA – November 9, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Q3 2020 Financial Results 05 November 2020
ObsEva Announces Third Quarter 2020 Financial Results and Business Update
Positive Phase 3 PRIMROSE 1 and 2 trial results of linzagolix for the treatment of heavy menstrual bleeding due to…